Loading...
Docoh

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.

Company profile

ALDX stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 121.01M 121.01M 121.01M 121.01M 121.01M 121.01M
Cash burn (monthly) 12.63M 10.73M 5.9M 5.42M 6.65M 4.4M
Cash used (since last report) 18.34M 15.57M 8.57M 7.87M 9.66M 6.39M
Cash remaining 102.67M 105.44M 112.44M 113.14M 111.35M 114.62M
Runway (months of cash) 8.1 9.8 19.0 20.9 16.7 26.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Aug 22 Perceptive Advisors Common Stock Buy Acquire P Yes No 7.85 15,000 117.75K 11,350,085
9 Aug 22 Perceptive Advisors Common Stock Buy Acquire P Yes No 7.5 100,000 750K 11,335,085
8 Aug 22 Perceptive Advisors Common Stock Buy Acquire P Yes No 7.24 97,000 702.28K 11,235,085
5 Aug 22 Perceptive Advisors Common Stock Buy Acquire P Yes No 6.95 141,000 979.95K 11,138,085
4 Aug 22 Perceptive Advisors Common Stock Buy Acquire P Yes No 6.17 95,100 586.77K 10,997,085
3 Aug 22 Perceptive Advisors Common Stock Buy Acquire P Yes No 5.84 100,000 584K 10,901,985
66.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 110 117 -6.0%
Opened positions 18 24 -25.0%
Closed positions 25 23 +8.7%
Increased positions 34 39 -12.8%
Reduced positions 37 34 +8.8%
13F shares Current Prev Q Change
Total value 171.72M 186.28M -7.8%
Total shares 38.62M 36.48M +5.8%
Total puts 561.1K 777.1K -27.8%
Total calls 566.1K 1.85M -69.5%
Total put/call ratio 1.0 0.4 +136.5%
Largest owners Shares Value Change
Perceptive Advisors 9.9M $44.02M 0.0%
BLK Blackrock 3.22M $14.32M -0.3%
Vanguard 2.96M $13.17M +5.2%
Citadel Advisors 2.48M $11.02M +759.1%
Verition Fund Management 2.11M $9.36M +54.1%
Eagle Asset Management 1.47M $6.55M +5.8%
Tri Locum Partners 1.45M $6.43M NEW
Prosight Management 1.4M $6.22M +21.2%
GS Goldman Sachs 1.39M $6.18M +1254.9%
Assenagon Asset Management 975.14K $4.33M +3594.8%
Largest transactions Shares Bought/sold Change
STT State Street 877.8K -2.2M -71.5%
Citadel Advisors 2.48M +2.19M +759.1%
Tri Locum Partners 1.45M +1.45M NEW
GS Goldman Sachs 1.39M +1.29M +1254.9%
Millennium Management 504.46K -1.15M -69.6%
Assenagon Asset Management 975.14K +948.75K +3594.8%
UBS UBS Group AG - Registered Shares 960.39K +776.59K +422.5%
Woodline Partners 36.86K -739.38K -95.3%
Verition Fund Management 2.11M +739.21K +54.1%
683 Capital Management 500K +500K NEW

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: crossover, half, mm, Schirmer, trail
Removed: confirmed, measuring, precedent, validated, validating

Patents

Utility
Toxic Aldehyde Related Diseases and Treatment
30 Jun 22
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
Utility
Combination Treatment of Ocular Inflammatory Disorders and Diseases
16 Jun 22
The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases.
Utility
Formulations for Treatment of Dry Eye Disease
5 May 22
The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
Utility
Injectable Formulations
5 May 22
The present disclosure relates to therapeutic compounds and formulations for treating, reducing the risk of, or for preventing a disease, disorder, or condition characterized by the presence of toxic aldehydes.
Utility
Polymorphic compounds and uses thereof
26 Apr 22
The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.

Reddit threads